Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767
dowens@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742
drosen@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

April 7, 2005

Bextra Ban a Good Step, But FDA Should Pull Celebrex Too

Statement of Sidney M. Wolfe, M.D., Director, Public Citizen’s Health Research Group

In January, Public Citizen petitioned to have Bextra and Celebrex, two COX-2 inhibitors, removed from the market because they increase the risk of heart attacks. Today, the U.S. Food and Drug Administration (FDA) has called on Pfizer to pull Bextra from the shelves and place a warning on Celebrex.

While we are pleased that the FDA has taken Bextra off the market, it has recklessly allowed Celebrex to continue to be sold. An unpublished study finished in 2000 indicated increased cardiac risks associated with Celebrex.

Last year, almost twice as many prescriptions were written for Celebrex as for Bextra – 23.9 million prescriptions compared to 12.9 million. Neither Bextra nor Celebrex protects the gastrointestinal tract as drugmakers claim. Given that neither drug has any unique benefits but both carry unique cardiac risks, it is unconscionable to leave Celebrex on the market.

In addition, the FDA is sowing dangerous confusion by requiring all nonsteroidal anti-inflammatory drugs (NSAIDs) – Celebrex and all non-aspirin NSAIDs – to warn about increased cardiac risks, even though the risks of Celebrex are clearly higher than at least one NSAID, naproxen.

The FDA said today that it took its actions “based on the available scientific data, including data accumulated since the drugs were approved.” But the agency’s job is to ensure that drugs with risks that outweigh the benefits are taken off the market. We call on Congress, which is finally delving into FDA’s operations, to investigate why the agency is not also pulling the equally dangerous Celebrex from the shelves.

Note: Bextra is the tenth prescription drug to be taken off the market in the past seven years that Public Citizen had previously warned consumers not to use. For four of the drugs – Vioxx, Baycol, Rezulin and Serzone – Public Citizen issued warnings more than two years before their removal from the market. In April 2001, Public Citizen warned patients not to use Celebrex. Public Citizen maintains a comprehensive prescription drug database at www.WorstPills.org.

###

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.